UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
Kinase Fusion Gene:ACER3_MAPK9 |
Kinase Fusion Protein Summary |
Kinase Fusion gene summary |
Kinase Fusion partner gene information | Kinase Fusion gene name: ACER3_MAPK9 | KinaseFusionDB ID: KFG111 | FusionGDB2.0 ID: KFG111 | Hgene | Tgene | Gene symbol | ACER3 | MAPK9 | Gene ID | 55331 | 5601 | |
Gene name | alkaline ceramidase 3 | mitogen-activated protein kinase 9 | ||||||||||
Synonyms | APHC|PHCA|PLDECO | JNK-55|JNK2|JNK2A|JNK2ALPHA|JNK2B|JNK2BETA|PRKM9|SAPK|SAPK1a|p54a|p54aSAPK | ||||||||||
Cytomap | 11q13.5 | 5q35.3 | ||||||||||
Type of gene | protein-coding | protein-coding | ||||||||||
Description | alkaline ceramidase 3alkCDase 3alkaline CDase 3alkaline dihydroceramidase SB89alkaline phytoceramidasephytoceramidase, alkaline | mitogen-activated protein kinase 9Jun kinaseMAP kinase 9MAPK 9c-Jun N-terminal kinase 2c-Jun kinase 2stress-activated protein kinase 1astress-activated protein kinase JNK2 | ||||||||||
Modification date | 20240411 | 20240411 | ||||||||||
UniProtAcc | Q9NUN7 | P45984 | ||||||||||
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000526597, ENST00000530182, ENST00000532485, ENST00000533873, ENST00000538157, ENST00000544113, | ENST00000343111, ENST00000393360, ENST00000452135, ENST00000455781, ENST00000347470, ENST00000397072, ENST00000425491, ENST00000524170, ENST00000539014, | |||||||||
Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: ACER3 [Title/Abstract] AND MAPK9 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | ACER3(76647583)-MAPK9(179661856), # samples:1 |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | ACER3 | GO:0043067 | regulation of programmed cell death | 20068046 |
Hgene | ACER3 | GO:0046512 | sphingosine biosynthetic process | 20068046 |
Hgene | ACER3 | GO:0046514 | ceramide catabolic process | 30575723 |
Hgene | ACER3 | GO:0071602 | phytosphingosine biosynthetic process | 11356846|20068046 |
Tgene | MAPK9 | GO:0007254 | JNK cascade | 8654373 |
Tgene | MAPK9 | GO:0034614 | cellular response to reactive oxygen species | 34048572 |
Tgene | MAPK9 | GO:0090594 | inflammatory response to wounding | 27830702 |
Tgene | MAPK9 | GO:1900017 | positive regulation of cytokine production involved in inflammatory response | 8654373 |
Kinase Fusion gene breakpoints across ACER3 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Kinase Fusion gene breakpoints across MAPK9 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
Kinase Fusion gene information. |
Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
ChiTaRS5.0 | AA169474 | ACER3 | chr11 | 76647583 | MAPK9 | chr5 | 179661856 |
Top |
Kinase Fusion ORF Analysis |
Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:76647583/:179661856) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
ACER3 | MAPK9 |
FUNCTION: Endoplasmic reticulum and Golgi ceramidase that catalyzes the hydrolysis of unsaturated long-chain C18:1-, C20:1- and C20:4-ceramides, dihydroceramides and phytoceramides into sphingoid bases like sphingosine and free fatty acids at alkaline pH (PubMed:20068046, PubMed:26792856, PubMed:20207939, PubMed:11356846, PubMed:30575723). Ceramides, sphingosine, and its phosphorylated form sphingosine-1-phosphate are bioactive lipids that mediate cellular signaling pathways regulating several biological processes including cell proliferation, apoptosis and differentiation (PubMed:20068046). Controls the generation of sphingosine in erythrocytes, and thereby sphingosine-1-phosphate in plasma (PubMed:20207939). Through the regulation of ceramides and sphingosine-1-phosphate homeostasis in the brain may play a role in neurons survival and function (By similarity). By regulating the levels of pro-inflammatory ceramides in immune cells and tissues, may modulate the inflammatory response (By similarity). {ECO:0000250|UniProtKB:Q9D099, ECO:0000269|PubMed:11356846, ECO:0000269|PubMed:20068046, ECO:0000269|PubMed:20207939, ECO:0000269|PubMed:26792856, ECO:0000269|PubMed:30575723, ECO:0000303|PubMed:20068046}. | FUNCTION: Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. Extracellular stimuli such as pro-inflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2. In turn, MAPK9/JNK2 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional activity. In response to oxidative or ribotoxic stresses, inhibits rRNA synthesis by phosphorylating and inactivating the RNA polymerase 1-specific transcription initiation factor RRN3. Promotes stressed cell apoptosis by phosphorylating key regulatory factors including TP53 and YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized differentiation of T-helper cells into Th1 cells. Upon T-cell receptor (TCR) stimulation, is activated by CARMA1, BCL10, MAP2K7 and MAP3K7/TAK1 to regulate JUN protein levels. Plays an important role in the osmotic stress-induced epithelial tight-junctions disruption. When activated, promotes beta-catenin/CTNNB1 degradation and inhibits the canonical Wnt signaling pathway. Participates also in neurite growth in spiral ganglion neurons. Phosphorylates the CLOCK-BMAL1 heterodimer and plays a role in the regulation of the circadian clock (PubMed:22441692). Phosphorylates POU5F1, which results in the inhibition of POU5F1's transcriptional activity and enhances its proteasomal degradation (By similarity). {ECO:0000250|UniProtKB:Q9WTU6, ECO:0000269|PubMed:22441692}.; FUNCTION: MAPK9 isoforms display different binding patterns: alpha-1 and alpha-2 preferentially bind to JUN, whereas beta-1 and beta-2 bind to ATF2. However, there is no correlation between binding and phosphorylation, which is achieved at about the same efficiency by all isoforms. JUNB is not a substrate for JNK2 alpha-2, and JUND binds only weakly to it. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of ACER3_MAPK9 |
Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
MAPK9 | P45984-2 | human | MFN2 | O95140 | S27 | HMAEVNAsPLkHFVT | |
MAPK9 | P45984-2 | human | STAT3 | P40763 | S727 | NtIDLPMsPrTLDSL | |
MAPK9 | P45984 | human | YAP1 | P46937-3 | T154 | VVSGPAAtPTAQHLR | |
MAPK9 | P45984 | human | MAPT | P10636-8 | T231 | KKVAVVRtPPKsPss | |
MAPK9 | P45984 | human | ATF2 | P15336 | T69 | sVIVADQtPtPtRFL | |
MAPK9 | P45984 | human | APP | P05067-4 | T668 | VEVDAAVtPEERHLs | APP_amyloid |
MAPK9 | P45984 | human | ATF2 | P15336 | T71 | IVADQtPtPtRFLkN | |
MAPK9 | P45984 | human | JDP2 | Q8WYK2 | T148 | VRtDsVKtPEsEGNP | |
MAPK9 | P45984 | human | KLF13 | Q9Y2Y9 | S119 | GAAAAPPsPAWsEPE | |
MAPK9 | P45984 | human | TOB1 | P50616 | S154 | SSVSSsPsPPFGHSA | |
MAPK9 | P45984 | human | YAP1 | P46937-3 | T119 | AGTAGALtPQHVRAH | |
MAPK9 | P45984 | human | NFATC4 | Q14934 | S217 | GLGsPLPsPRAsPRP | |
MAPK9 | P45984 | human | KLF13 | Q9Y2Y9 | S123 | APPsPAWsEPEPEAG | |
MAPK9 | P45984 | human | PDX1 | P52945 | S66 | QGsPPDIsPYEVPPL | |
MAPK9 | P45984 | human | LIMD1 | Q9UGP4 | S277 | RVsPGLPsPNLENGA | |
MAPK9 | P45984 | human | LIMD1 | Q9UGP4 | S272 | TASsQRVsPGLPsPN | |
MAPK9 | P45984 | human | BCL2L1 | Q07817 | T115 | LTSQLHItPGTAYQS | Bcl-2 |
MAPK9 | P45984 | human | ATF2 | P15336 | S90 | GLFNELAsPFENEFk | |
MAPK9 | P45984 | human | TP53 | P04637 | S46 | AMDDLMLsPDDIEQW | TAD2 |
MAPK9 | P45984 | human | BAZ1B | Q9UIG0 | S158 | ksDGACDsPssDKEN | |
MAPK9 | P45984 | human | CDC25C | P30307 | S168 | SEMKyLGsPIttVPK | |
MAPK9 | P45984 | human | SLC6A4 | P31645 | T616 | IKsItPEtPTEIPCG | |
MAPK9 | P45984 | human | YAP1 | P46937-3 | S317 | GTQNPVSsPGMSQEL | |
MAPK9 | P45984 | human | BID | P55957 | T59 | EGyDELQtDGNRsSH | BID |
MAPK9 | P45984 | human | LIMD1 | Q9UGP4 | S421 | LGSVLLDsPssPRVr | |
MAPK9 | P45984 | human | PIN1 | Q13526 | S115 | sQFSDCssAkARGDL | Rotamase |
MAPK9 | P45984 | human | PSEN1 | P49768 | S319 | NskyNAEstEREsQD | Presenilin |
MAPK9 | P45984 | human | DCX | O43602-2 | T321 | TSSSQLStPKSKQsP | |
MAPK9 | P45984 | human | NFATC3 | Q12968 | S163 | SYRESSLsPsPASSI | |
MAPK9 | P45984 | human | BCL2L1 | Q07817 | S62 | PSWHLADsPAVNGAT | |
MAPK9 | P45984 | human | DCX | O43602-2 | S334 | sPIStPTsPGSLRkH | |
MAPK9 | P45984 | human | CDKN1A | P38936 | S98 | GGRRPGTsPALLQGT | |
MAPK9 | P45984 | human | FOXO4 | P98177 | T451 | PIPKALGtPVLtPPt | |
MAPK9 | P45984 | human | SREBF1 | P36956 | S117 | YPSMPAFsPGPGIkE | |
MAPK9 | P45984 | human | GORASP1 | Q9BQQ3 | S274 | DPLPGPGsPSHsAPD | |
MAPK9 | P45984 | human | DCX | O43602-2 | T331 | SKQsPIStPTsPGSL | |
MAPK9 | P45984 | human | MAPT | P10636-8 | S202 | sGyssPGsPGtPGsR | |
MAPK9 | P45984 | human | MYC | P01106 | S86 | sRRsGLCsPSyVAVt | Myc_N |
MAPK9 | P45984 | human | PSEN1 | P49768 | T320 | skyNAEstEREsQDT | Presenilin |
MAPK9 | P45984 | human | CDKN1A | P38936 | S130 | sGEQAEGsPGGPGDs | |
MAPK9 | P45984 | human | RXRA | P19793 | S260 | NMGLNPssPNDPVtN | Hormone_recep |
MAPK9 | P45984 | human | YAP1 | P46937-3 | S138 | SLQLGAVsPGTLTPT | |
MAPK9 | P45984 | human | BCL2L1 | Q07817 | T47 | GTESEMEtPsAINGN | |
MAPK9 | P45984 | human | TOB1 | P50616 | S152 | PASSVSSsPsPPFGH | |
MAPK9 | P45984 | human | MAPT | P10636-8 | T217 | sRtPsLPtPPtREPK | |
MAPK9 | P45984 | human | NFATC4 | Q14934 | S213 | ASRFGLGsPLPsPRA | |
MAPK9 | P45984 | human | NFATC3 | Q12968 | S165 | RESSLsPsPASSISs | |
MAPK9 | P45984 | human | JUN | P05412 | S73 | VGLLkLAsPELERLI | Jun |
MAPK9 | P45984 | human | TP53 | P04637 | S20 | PLsQEtFsDLWkLLP | P53_TAD |
MAPK9 | P45984 | human | MAPT | P10636-8 | T181 | ktPPAPktPPssGEP | |
MAPK9 | P45984 | human | MAPKAPK5 | Q8IW41 | T182 | IDQGDLMtPQFtPyY | Pkinase |
MAPK9 | P45984 | human | MARCKS | P29966 | S46 | VKVNGDAsPAAAEsG | MARCKS |
MAPK9 | P45984 | human | JUN | P05412 | S63 | kNsDLLtsPDVGLLk | Jun |
MAPK9 | P45984 | human | MYC | P01106 | S77 | LLPtPPLsPsRRsGL | Myc_N |
MAPK9 | P45984 | human | CDK4 | P11802 | T172 | YSYQMALtPVVVTLW | Pkinase |
MAPK9 | P45984 | human | PDX1 | P52945 | S61 | LGALEQGsPPDIsPY | |
MAPK9 | P45984 | human | MAPT | P10636-8 | T212 | tPGsRsRtPsLPtPP | |
MAPK9 | P45984 | human | TAB1 | Q15750 | S438 | tPTLTNQsPTLtLQS | |
MAPK9 | P45984 | human | MAPK8IP1 | Q9UQF2 | T103 | LIDAtGDtPGAEDDE | |
MAPK9 | P45984 | human | LIMD1 | Q9UGP4 | S424 | VLLDsPssPRVrLPC | |
MAPK9 | P45984 | human | TOB1 | P50616 | S164 | FGHSAAVsPTFMPRS | |
MAPK9 | P45984 | human | FOXO4 | P98177 | T455 | ALGtPVLtPPtEAAS | |
MAPK9 | P45984 | human | RRN3 | Q9NYV6 | T200 | IARYVPstPWFLMPI | RRN3 |
MAPK9 | P45984 | human | CDKN1A | P38936 | T57 | NFDFVtEtPLEGDFA | CDI |
MAPK9 | P45984 | human | YAP1 | P46937-3 | T362 | SSySVPRtPDDFLNS | |
MAPK9 | P45984 | human | APLP2 | Q06481 | T736 | VEVDPMLtPEERHLN | APP_amyloid |
Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
Enriched GO biological processes of the phosphorylation target genes of the kinase |
Kinase | GOID | GO term | P.adjust |
MAPK9 | ID | Description | 0.00e+00 |
MAPK9 | GO:1902893 | regulation of miRNA transcription | 5.24e-08 |
MAPK9 | GO:0061614 | miRNA transcription | 5.24e-08 |
MAPK9 | GO:2000628 | regulation of miRNA metabolic process | 1.24e-07 |
MAPK9 | GO:0097193 | intrinsic apoptotic signaling pathway | 1.24e-07 |
MAPK9 | GO:0140747 | regulation of ncRNA transcription | 1.34e-07 |
MAPK9 | GO:0010586 | miRNA metabolic process | 2.85e-07 |
MAPK9 | GO:2001233 | regulation of apoptotic signaling pathway | 6.02e-07 |
MAPK9 | GO:0098781 | ncRNA transcription | 1.32e-06 |
MAPK9 | GO:0009299 | mRNA transcription | 7.25e-06 |
MAPK9 | GO:0010332 | response to gamma radiation | 7.25e-06 |
MAPK9 | GO:1902895 | positive regulation of miRNA transcription | 7.28e-06 |
MAPK9 | GO:0006839 | mitochondrial transport | 8.18e-06 |
MAPK9 | GO:2001242 | regulation of intrinsic apoptotic signaling pathway | 8.18e-06 |
MAPK9 | GO:1902749 | regulation of cell cycle G2/M phase transition | 9.85e-06 |
MAPK9 | GO:2000630 | positive regulation of miRNA metabolic process | 1.54e-05 |
MAPK9 | GO:0072594 | establishment of protein localization to organelle | 1.57e-05 |
MAPK9 | GO:0071480 | cellular response to gamma radiation | 1.94e-05 |
MAPK9 | GO:0050673 | epithelial cell proliferation | 2.04e-05 |
MAPK9 | GO:2001234 | negative regulation of apoptotic signaling pathway | 2.99e-05 |
MAPK9 | GO:0044839 | cell cycle G2/M phase transition | 3.85e-05 |
MAPK9 | GO:0051402 | neuron apoptotic process | 6.69e-05 |
MAPK9 | GO:0071478 | cellular response to radiation | 8.68e-05 |
MAPK9 | GO:0008630 | intrinsic apoptotic signaling pathway in response to DNA damage | 1.04e-04 |
MAPK9 | GO:0010389 | regulation of G2/M transition of mitotic cell cycle | 1.10e-04 |
MAPK9 | GO:0034504 | protein localization to nucleus | 1.13e-04 |
MAPK9 | GO:0042789 | mRNA transcription by RNA polymerase II | 1.13e-04 |
MAPK9 | GO:0048144 | fibroblast proliferation | 1.13e-04 |
MAPK9 | GO:1901987 | regulation of cell cycle phase transition | 1.13e-04 |
MAPK9 | GO:0044772 | mitotic cell cycle phase transition | 1.37e-04 |
MAPK9 | GO:2001243 | negative regulation of intrinsic apoptotic signaling pathway | 1.38e-04 |
MAPK9 | GO:0007006 | mitochondrial membrane organization | 1.73e-04 |
MAPK9 | GO:0070482 | response to oxygen levels | 1.77e-04 |
MAPK9 | GO:0031667 | response to nutrient levels | 1.77e-04 |
MAPK9 | GO:1901990 | regulation of mitotic cell cycle phase transition | 2.10e-04 |
MAPK9 | GO:0046902 | regulation of mitochondrial membrane permeability | 2.67e-04 |
MAPK9 | GO:0010212 | response to ionizing radiation | 2.88e-04 |
MAPK9 | GO:0043470 | regulation of carbohydrate catabolic process | 2.88e-04 |
MAPK9 | GO:0000086 | G2/M transition of mitotic cell cycle | 3.00e-04 |
MAPK9 | GO:1904019 | epithelial cell apoptotic process | 3.35e-04 |
MAPK9 | GO:0001701 | in utero embryonic development | 3.41e-04 |
MAPK9 | GO:0097284 | hepatocyte apoptotic process | 3.51e-04 |
MAPK9 | GO:0006979 | response to oxidative stress | 3.71e-04 |
MAPK9 | GO:0071479 | cellular response to ionizing radiation | 3.78e-04 |
MAPK9 | GO:0010821 | regulation of mitochondrion organization | 3.86e-04 |
MAPK9 | GO:0007178 | transmembrane receptor protein serine/threonine kinase signaling pathway | 4.06e-04 |
MAPK9 | GO:0090559 | regulation of membrane permeability | 4.65e-04 |
MAPK9 | GO:0006606 | protein import into nucleus | 4.78e-04 |
MAPK9 | GO:0009314 | response to radiation | 5.03e-04 |
MAPK9 | GO:0048143 | astrocyte activation | 5.05e-04 |
Top |
Related Drugs to ACER3_MAPK9 |
Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Distribution of the number of studies mentioning ACER3-MAPK9 and kinase inhibitors the PubMed Abstract (04-01-2024) |
Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to ACER3_MAPK9 |
Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
MeSH ID | MeSH term |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
Clinical Trials from clinicaltrials.gov (06-17-2024) |
Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |